Search research articles
Contact Us
Filters
Showing results (301-310 of 332) with videos related to
Page
of 34
Sort By:
European Urology
|
May 14, 2014
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer
Grant D Stewart, Fiach C O'Mahony, Alexander Laird, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Cancer Immunology Research
|
May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu, Anh Hoang, Lijun Zhou, et al.
European Urology Oncology
|
August 19, 2025
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Cristiane D Bergerot, David Cella, Paulo G Bergerot, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 26, 2026
Clinical outcomes of stereotactic MRI-guided adaptive radiotherapy for renal tumors in patients with a solitary kidney
Claire van Vliet, Joyce Caro, Omar Bohoudi, et al.
JAMA Oncology
|
December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
Axel Bex, Peter Mulders, Michael Jewett, et al.
European Urology
|
June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)
Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
The Oncologist
|
March 14, 2023
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, et al.
Page
of 34
Search research articles
Search
Showing results (301-310 of 332) with videos related to
Sort By:
Page
of 34
European Urology
|
May 14, 2014
Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer
Grant D Stewart, Fiach C O'Mahony, Alexander Laird, et al.
Lancet (London, England)
|
February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
Bhavna Oza, Tim Eisen, Eleni Frangou, et al.
Cancer Immunology Research
|
May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu, Anh Hoang, Lijun Zhou, et al.
European Urology Oncology
|
August 19, 2025
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
Cristiane D Bergerot, David Cella, Paulo G Bergerot, et al.
Targeted Oncology
|
September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Robert J Motzer, Paul Russo, Viktor Grünwald, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 26, 2026
Clinical outcomes of stereotactic MRI-guided adaptive radiotherapy for renal tumors in patients with a solitary kidney
Claire van Vliet, Joyce Caro, Omar Bohoudi, et al.
JAMA Oncology
|
December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
Axel Bex, Peter Mulders, Michael Jewett, et al.
European Urology
|
June 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME)
Roderick Emile De Bruijn, Peter Mulders, Michael A Jewett, et al.
The Oncologist
|
March 14, 2023
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, et al.
Page
of 34